by admin | Apr 16, 2024 | Uncategorized
A recent Phase 2b human clinical study involving Tecrea’s Nanocin technology as part of a novel topical terbinafine antifungal product, has met the primary endpoint (BBTAF202) in patients with onychomycosis, showing superiority over placebo (vehicle) with a high...
by admin | Apr 16, 2024 | Uncategorized
Tecrea Ltd. is thrilled to announce the successful completion of the NBIC FTMA award, which was used for an industry-academia exchange and collaboration with the Bladder Infection and Immunity Group, UCL. This grant has facilitated a fruitful exchange of knowledge and...
